23: Impact of Tumour Volume and the Surrogate Effect of Lymph Node Location on the Risk of Distant Metastasis in Nasopharyngeal Cancer  by Rathod, Shrinivas et al.
CARO 2016                                                                                                                                                                  S9 
_________________________________________________________________________________________________________ 
22 
DID THE ADDITION OF CHEMOTHERAPY TO CONVENTIONAL 
RADIOTHERAPY IMPROVE OUTCOMES IN TREATMENT OF 
OROPHARYNX CANCER IN ONTARIO, CANADA – A MARKER-
TREATMENT INTERACTION STUDY? 
Stephen Hall1, Fei-Fei Liu2, Brian O'Sullivan2, Patti Groome1, 
Willa Shi2 
1Queen's University, Kingston, ON 
2University of Toronto, Toronto, ON 
 
Purpose: In 2001 the management of head and neck cancer 
abruptly changed with the addition of concurrent chemotherapy 
to radiotherapy based on randomized trials and meta-analyses. 
The role of Human Papilloma Virus (HPV) and its prognostic 
impact were subsequently identified in 2004. However there is 
no evidence on the efficacy of concurrent chemoradiotherapy 
(CRT) specifically for HPV positive or negative patients over 
conventional radiotherapy (RT). The objective of this study was 
to compare treatment effectiveness by HPV status based on a 
group of patients including those treated before and after CRT 
was adopted across the cancer centres of Ontario, Canada. 
Methods and Materials: A treatment-effectiveness and marker-
treatment interaction study of OPC patients treated for cure in 
1998, 1999, 2003 and 2004 from all treatment centres in Ontario 
who had available tissue for HPV testing. The patients were 
identified using the Ontario Cancer Registry and all charts were 
reviewed for demographic, patient, treatment and outcome 
factors. 865 patients were treated for cure and tissue was 
available on 610. Samples were tested for p16 and if negative 
were tested again using in-situ hybridization for HPV p16/18 viral 
DNA. We compared the survival of patients by HPV status and by 
treatment (RT versus CRT) using the Kaplan-Meier method and 
Cox Multiple Hazards regression models. 
Results: There were 392 HPV positive patients and 199 of the 610 
were treated with CRT. The HPV positive patients had 40% better 
overall survival (OS) and CRT improved OS by 15% over RT alone. 
However, there was no difference in OS comparing CRT to RT 
alone for the HPV positive patients (log rank p = 0.57) or for the 
HPV negative group (p = 0.15). When the multiple variable 
analysis was performed including HPV status and the interaction 
term with treatment, the HR for treatment (RT versus CRT) for 
HPV positive was 1.003 and for HPV negative was 1.036, and the 
p value for the interaction term was 0.91 indicating an outcome 
driven by HPV status not treatment type. 
Conclusions: In this study of real-world patients what appeared 
to be improvement in OS with the addition of concurrent 
chemotherapy to conventional radiotherapy was confounded by 
HPV status.  
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Purpose: With the advent of IMRT, distant metastasis (DM) has 
emerged as the most common cause of death in nasopharyngeal 
cancer (NPC). Lower neck lymph node (LWNK-LN) involvement is 
considered a poor prognostic factor and has traditionally been 
included in the most adverse N-category of the NPC TNM 
classification. NPC tends not to develop isolated spread to 
discontiguous lymph node (LN) echelons and LWNK-LN may 
correspondingly represent a continuum in the total burden of 
lymph node disease. This study evaluates whether tumour 
volume and the presence of LWNK-LN have independent 
influence on DM of NPC. 
Methods and Materials: All newly diagnosed NPC treated with 
IMRT +/- chemotherapy from 2005-2013 were reviewed. Primary 
(GTV-T) and nodal (GTV-N) volumes were delineated during IMRT 
treatment and subjected to institutional peer review. LWNK-LN 
was defined as level IV/Vb (any extension below the caudal 
border of the cricoid cartilage) based on the recently proposed 
8th edition TNM for NPC (Pan JJ, et al., Cancer 2016; 122(4):546-
58). Univariate (UVA) and multivariate (MVA) analyses was 
performed to evaluate prognostic significance of GTV-T, GTV-N 
and LWNK-LN for DM for the entire and LN-positive (N+) cohort. 
Results: A total of 344 NPC were identified including 52- N0, 87- 
N1, 158- N2, 16- N3a, and 31- N3b by 7th edition TNM. Median 
GTV-T was 25 cc (range: 1-253) and GTV-N was 14 cc (range: 0-
685). LWNK-LNs were present in 68 (19.7%) cases, all of which 
also had LNs in the upper neck. LWNK-LN were associated with 
higher GTV-N (p < 0.01). Median follow up was 5.6 years. In UVA, 
higher GTV-T (< 25 versus ≥ 25 cc) was associated with inferior 
five-year distant control (DC) [96% versus 78%; p < 0.001]. Higher 
GTV-N (< 14 versus ≥ 14 cc) was also associated with inferior five-
year DC [92% versus 82%; p = 0.02]. Presence of LWNK-LN was 
associated with inferior five-year DC [90% versus 75%; < 0.01]. 
MVA for DC showed that GTV-T [HR: 1.07 (1 -1.13), p < 0.01], 
GTV-N [HR: 1.1 (1.06-1.13), p = 0.03] and T classification [HR: 
2.71 (1.26 -5.83), p = 0.01] were prognostic while LWNK-LN was 
not [HR: 1.27 (0.65-2.47), p = 0.48]. Identical analyses confined 
to the N+ subset also confirmed the same findings that GTV-T 
[HR: 1.08 (1 -1.16), p = 0.04], GTV-N [HR: 1.09 (1.05-1.13), p < 
0.001] and T classification [HR: 2.36 (1.03 -5.40), p = 0.04] were 
prognostic for DC but LWNK-LN was not [HR: 1.31 (0.67-2.58), p 
= 0.43]. 
Conclusions: This study shows that primary and nodal volume are 
both prognostic for risk of DM after accounting for T and N 
classification. LWNK-LN has no apparent effect on DM risk after 
accounting for tumour volume, suggesting LWNK-LN is likely a 
surrogate of higher nodal volume rather than related to its 
anatomic location. 
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Purpose: Surgical transfer of the submandibular gland to the 
submental space in patients with non-oral head and neck cancer 
prior to adjuvant radiotherapy (RT) has previously been found to 
reduce the incidence of long-term xerostomia. Patients with oral 
cavity cancer are not candidates for the traditional 
submandibular gland transfer (SGT), as the submental space is 
commonly irradiated. A modified submandibular gland transfer 
(mSGT) technique was developed in which the contralateral 
gland is transferred to the peri-parotid space, lateral to the 
mandible. This study aimed to determine if the dose reduction 
to the submandibular gland achieved with mSGT results in mean 
doses below commonly accepted dose constraints, potentially 
reducing rates of longterm xerostomia. 
Methods and Materials: Sixteen consecutive patients with 
indications for adjuvant RT following surgery were enrolled. The 
mSGT was carried out at the time of oncologic resection. For 
each patient, a planning CT scan was performed and a RT plan 
was generated for volumetric-modulated arc therapy, with 
conformal avoidance of the transferred gland and parotid if the 
contralateral neck was pN0. The dose prescribed was 60 Gy in 30 
fractions to the tumour bed and involved nodal regions and 54 
Gy in 30 fractions to areas at risk of subclinical spread. Doses to 
the transferred gland and its original location in the 
submandibular triangle were compared. 
Results: In all patients the submandibular gland could be 
successfully transferred and adjuvant RT delivered according to 
protocol. The median dose to the transferred submandibular 
gland was 26.30 Gy (Range: 8.78 to 56.23 Gy) which was 
significantly lower than the median dose of 55.56 Gy to the 
